Strides Drug Patent Portfolio
Strides owns 2 orange book drugs protected by 7 US patents Given below is the list of Strides's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11491125 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | 29 Sep, 2041 | Active |
| US11850225 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | 29 Sep, 2041 | Active |
| US10792262 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | 29 Jul, 2039 | Active |
| US11654124 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | 29 Jul, 2039 | Active |
| US11931328 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | 29 Jul, 2039 | Active |
| US5612367 | Method of enhancing bioavailability of pharmaceutical agents | 18 Mar, 2014 | Expired |
| US5482963 | Pharmaceutical agents useful as leukotriene antagonists | 09 Jan, 2013 | Expired |
Latest Legal Activities on Strides's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Strides.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 14 May, 2024 | US11850225 |
| Recordation of Patent eCertificate of Correction | 14 May, 2024 | US11850225 |
| Patent eCofC Notification | 14 May, 2024 | US11850225 |
| Mail Patent eCofC Notification | 14 May, 2024 | US11850225 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Apr, 2024 | US10792262 |
| Patent eGrant Notification | 19 Mar, 2024 | US11931328 |
|
Recordation of Patent Grant Mailed
Critical
| 19 Mar, 2024 | US11931328 |
| Mail Patent eGrant Notification | 19 Mar, 2024 | US11931328 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 19 Mar, 2024 | US11931328 |
| Recordation of Patent eGrant | 19 Mar, 2024 | US11931328 |
|
Email Notification
Critical
| 19 Mar, 2024 | US11931328 |
|
Email Notification
Critical
| 29 Feb, 2024 | US11931328 |
|
Issue Notification Mailed
Critical
| 28 Feb, 2024 | US11931328 |
| Mail Patent eCofC Notification | 20 Feb, 2024 | US11850225 |
|
Email Notification
Critical
| 20 Feb, 2024 | US11850225 |
Strides's Family Patents
Recent FDA approvals and tentative approvals for Strides
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Innovator drugs
Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Dolutegravir; Tenofovir Disoproxil Fumarate; Lamivudine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | New Combination and New Formulation or New Manufacturer | 14 Sep, 2023 |
| Stavudine; Lamivudine; Efavirenz |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 01 Jun, 2007 |
| Stavudine; Lamivudine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 13 Mar, 2007 |
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Lamivudine |
SUPPL-8
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Labeling | 14 Dec, 2016 |
| Tenofovir Disoproxil Fumarate |
SUPPL-6
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Labeling | 07 Dec, 2016 |
| Rilpivirine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 29 Sep, 2015 |
Strides Drug List
Given below is the complete list of Strides's drugs and the patents protecting them.
1. Accolate
Accolate is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5612367 | Method of enhancing bioavailability of pharmaceutical agents |
18 Mar, 2014
(11 years ago)
| Expired |
| US5482963 | Pharmaceutical agents useful as leukotriene antagonists |
09 Jan, 2013
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Accolate's drug page
2. Lyvispah
Lyvispah is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11491125 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
29 Sep, 2041
(15 years from now)
| Active |
| US11850225 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
29 Sep, 2041
(15 years from now)
| Active |
| US10792262 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
29 Jul, 2039
(13 years from now)
| Active |
| US11654124 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
29 Jul, 2039
(13 years from now)
| Active |
| US11931328 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
29 Jul, 2039
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lyvispah's drug page